Researchers Identified Key Driver of Tuberous Sclerosis

UC Berkeley scientists found hyperreactive astrocytes contribute to lesion formation in patients with the condition.

Updated on Sept. 23, 2026 in Alzheimer’s

Isometric editorial illustration of a 3D brain organoid in a petri dish on a laboratory bench. — UC Berkeley scientists identified hyperreactive astrocytes as a primary driver of lesion formation in patients with tuberous sclerosis complex. AI Illustration. Upload story photo >

Live Poll

Should federal research funding prioritize developing new treatments for rare pediatric genetic conditions?

Researchers at UC Berkeley have discovered that hyperreactive astrocytes act as a primary driver of lesion formation in tuberous sclerosis complex (TSC). The study, which analyzed brain tissue samples, suggests these cells may also share inflammatory gene signatures with common neurodegenerative disorders.

Why it matters

By identifying glial abnormalities as a root cause rather than a secondary effect of seizures, this research opens new pathways for targeted treatments. These findings may lead to therapies that silence reactive signaling without requiring systemic mTOR inhibition.

The study utilized single-cell transcriptomics to map gene expression in 10 pediatric TSC brain tissue samples. These cells displayed downregulated glutamate transporters and increased secretion of inflammatory cytokines.

The players

UC Berkeley

This public research university in California serves as a primary center for advanced neurobiological and genetic studies.

Stanford University

This research institution in California provided key co-authors who contributed to the collaborative study on TSC.

The details

The research team utilized 3D brain organoids cultivated for up to one year to mimic human perinatal development and track disease progression. Findings indicate that reactive astrocytes show elevated expression of APOE and CLU genes, contributing to the inflammatory environment that characterizes TSC lesions.

September 23, 2026: The study was published in Neuroscience News.

The Big Picture

This study shifts the scientific understanding of TSC by moving away from systemic mTOR inhibition as the sole therapeutic focus. It aligns with broader research into glial involvement in neurodegeneration, suggesting that astrocytes are primary drivers rather than secondary consequences of neurological conditions.

This discovery may eventually provide pediatric patients with drug-resistant epilepsy access to more precise, targeted immunosuppressive therapies. These future treatments could minimize the side effects associated with current systemic drug regimens.

The takeaway

This research highlights the critical role of astrocyte health in managing pediatric neurological disorders. Future medical strategies may prioritize silencing inflammatory glial signals to prevent lesion growth in patients with genetic mutations.